Multimodal single-cell assays provide high-resolution snapshots of complex cell populations, but are mostly limited to transcriptome plus an additional modality. Here, we describe expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq) for the high-throughput characterization of at least five modalities of information from each single cell. We demonstrate application of ECCITE-seq to multimodal CRISPR screens with robust direct single-guide RNA capture and to clonotype-aware multimodal phenotyping of cancer samples.
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) and synthetic markers of cell lineage (reviewed in ref. 2 ). Additionally, several approaches have recently been reported that allow detection of CRISPR-mediated perturbations along with the transcriptome of single cells using specialized vectors that link the expression of single-guide RNAs (sgRNAs) to separate transcripts that can be captured by standard scRNA-seq methods [3] [4] [5] [6] . Collectively, these methods enable the use of scRNA-seq as an unbiased readout of pooled CRISPR-based genetic screens, but all current methods suffer from limitations related to the need to determine the identity of the guide by a proxy polyadenylated transcript 7 . Previously, we and others have layered detection of proteins on top of scRNA-seq to enable integration of robust and well-characterized protein markers with unbiased transcriptomes of single cells 8, 9 . Our method, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) is compatible with oligo-dT based scRNAseq approaches and enables simultaneous protein detection using DNA oligo-labeled antibodies against cell surface markers. Given that protein levels are typically much higher than corresponding messenger RNAs (mRNAs), detection of proteins via antibodyderived tags (hereafter called protein tags) is a more robust measure of gene expression. In a series of experiments, we demonstrated the value of multimodal analysis to reveal phenotypes that could not be discovered using scRNA-seq alone 8 .
Here, we extend the use of CITE-seq and the related Cell Hashing method for multiplexing and doublet detection 10 , to 5′ capture-based scRNA-seq methods, exemplified by the 10x Genomics 5P/V(D)J system, allowing the detection of surface proteins together with the scRNA-seq and clonotype features. Oligos partially complementary to the gel bead-associated template switch oligos (TSO) in the 10x Genomics 5P/V(D)J kit were covalently conjugated to antibodies as described 10 and used to label cells. Annealing and extension during the reverse-transcription reaction associates the cell barcode and unique molecular identifier (UMI) from the gel bead oligo with the antibody tag in parallel with the mRNAs in the same droplet ( Fig. 1a ) (see Methods). Separate detection of expanded CRISPRcompatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq) protein tags and cell hashtags is achieved using different amplification handles 10 . We further adapt the system to enable direct and robust capture of sgRNAs from existing guide libraries and commonly used vectors compatible with pooled cloning. In contrast to commonly used 3′ tag scRNA-seq methods, the 10x Genomics 5P workflow appends the barcode via TSO, using a soluble poly(dT) oligo to prime reverse transcription, opening up the possibility of adding custom reversetranscription primers to sequences of interest. sgRNAs have a structure that lends themselves to direct capture: a variable region at the 5′ end and an invariant scaffold at the 3′ end 11, 12 . We leveraged the scaffold as an annealing site for an additional reverse-transcription primer, which after copying the variable guide sequence and template switching with the bead-derived TSO during reverse transcription, acquires a cell barcode and UMI in parallel with other modalities (mRNA, protein tags, hashtags) (Fig. 1a) . A mixture of human and mouse cells transduced with different sets of non-targeting sgRNAs was well-resolved by transcriptome, surface protein and sgRNA content, demonstrating the specificity of this approach (Fig. 1b, Supplementary Fig. 1a and Supplementary Tables 1 and 2) .
To illustrate the detection of six modalities (transcriptome, T-cell receptor (TCR) α/β and γ/δ, surface protein, sample identity by hashtags and sgRNA) in a single experiment ( Supplementary  Fig. 1b) , we generated a cell mixture comprising human peripheral blood mononuclear cells (PBMCs), two human T-cell lymphoma lines (MyLa and Sez4) and mouse NIH-3T3 cells that had been transduced with a library of non-targeting sgRNA-generating constructs (Fig. 1c and Supplementary Table 2 ). Cell hashtags specific to human cells were used to distinguish the three human samples, and the hashtag distribution was consistent with transcriptomebased clustering (Fig. 1c(i) ). ECCITE-seq antibodies directed against human or mouse CD29 label cells according to their species of origin (Fig. 1c(ii) ), illustrating the ability of ECCITE-seq to detect differentially expressed proteins within a sample. Clonotypes for TCR α/β (following 10x protocol) and TCR γ/δ (custom adaptation, see Methods) were detected in the PBMC and lymphoma cell clusters (Fig. 1c(iii) ). Finally, guide tags, derived directly from sgRNA molecules were specifically and robustly detected only in mouse cells (Fig. 1c(iv) ). The use of Cell Hashing together with sgRNA detection allowed us to distinguish between apparent 'doublets' where cells have been infected with two viruses (n = 325/390), from doublets resulting from co-encapsulation of two cells in the same droplet (n = 65/390) (Fig. 1d) . sgRNA capture was highly efficient, with sgRNAs detected in 93.5% of mouse cells (Fig. 1d) , in proportions consistent with genomic DNA-based detection from bulk cells (Supplementary Fig. 1c ). ECCITE-seq is designed to enable interrogation of single-cell transcriptomes together with surface protein markers in the context of CRISPR screens. To illustrate this, we infected K562 cells with a CRISPR library comprising guides targeting genes encoding cell surface markers (CD29 and CD46), intracellular signaling molecules (JAK1 and p53), as well as two non-targeting controls (Supplementary Table 1 ). We leveraged the Cell Hashing feature to remove cell doublets and observed very high rates of guide capture (confident detection of guide sequences in 98.3% of cells), in proportions consistent with genomic DNA-based detection ( Fig. 1d and Supplementary Fig. 1d ). Clustering on the basis of sgRNA counts of cells assigned to one guide revealed 13 distinct clusters, corresponding to the 13 guides in the experiment. Loss of expression of target genes at the level of mRNA and protein was readily apparent for ITGB1 (the gene encoding CD29 protein) and CD46 (Fig. 1e) and similarly apparent at the mRNA level for JAK1. To demonstrate that the capture of additional modalities has no detrimental effect on transcript capture, we performed scRNA-seq alone on the same aliquot of cells and confirmed no reduction in transcripts per cell ( Supplementary Fig. 1e ).
Cellular perturbations measured at transcript and protein level by ECCITE-seq reveal important features to consider, exemplified by CD46: most cells have detectable levels of protein, which collapse in cells with targeting sgRNAs (Supplementary Fig. 1f ). mRNA reduction is also apparent in cells with targeting sgRNAs, albeit less notably. Many cells have undetectable levels of CD46 mRNA even in the absence of targeting guides, probably reflecting the high dropout rates of scRNA-seq and the increased sensitivity that comes with protein detection.
The low drop-out of protein detection 8, 9 suggests that ECCITEseq could be more sensitive in detecting expression phenotypes than scRNA-seq alone. To test this for single genes, we compared clusters assigned to each given guide to the two non-targeting clusters and determined the P value of detecting the expected gene-expression change in randomly-sampled cells ranging from 10-100 per group. (Supplementary Fig. 1g ). The number of cells needed to detect the direct consequence of a given perturbation is markedly reduced when using protein detection as a readout compared to mRNA, increasing the numbers of perturbations that can be assessed for a given number of cells. Additionally, as exemplified by CD46, the gene-expression change triggered by two out of three sgRNAs (CD46.1 and CD46.3) was confidently detected only at the level of protein, even when considering all cells assigned to these sgRNAs. In practical terms, future applications of this technology will rely on detection of changes in gene-expression signatures and it stands to reason that these signatures will be more robust with protein components.
We next constructed a 49-marker panel of ECCITE-seq antibodies to deeply profile PBMCs from a healthy donor and a patient with cutaneous T-cell lymphoma (CTCL) ( Table 3 ) and prepared libraries for hashtags, protein tags, TCR α/β, TCR γ/δ and transcriptome. After hashtag demultiplexing to remove doublets, cells were clustered on the basis of transcriptome ( Fig. 2a and Supplementary Fig. 2 ). The majority of markers showed enrichment at the level of both protein and RNA (not shown) in expected clusters, consistent with our previous 3′ CITE-seq results 8 . We additionally recovered TCR α/β and γ/δ clonotype information for both the control and CTCL samples. Select markers and clonotypes are shown in Fig. 2a and Supplementary Fig. 2 .
For further comparative analysis, cells from both samples were computationally merged 13 and clustering based on either RNA or protein showed agreement in detecting most cell sub-populations and their gene-expression signatures (Supplementary Fig. 3 ). in silico gating based on CD3 and CD4 protein levels coupled with clonotypic information enabled differential gene-expression analysis comparing monoclonal T cells with polyclonal T cells from both the patient and the healthy donor sample (Fig. 2b,c) . This analysis reveals a distinct gene-expression signature of the malignant CTCL cells, consistent with previous studies 14 , and illustrates the power of ECCITE-seq to combine immunophenotype, clonotype and transcriptome information.
The enhancements to the CITE-seq toolkit enable detailed phenotypic and functional characterization of single cells. The recovery of clonotype information together with surface protein marker expression allowed fine separation of specific cell populations of interest, enabling careful determination of molecular phenotypes. Analogous to the use of TCR clonotype information in this study, we have recently used expressed mutations to define and further characterize clonal populations in scRNA-seq datasets (genotyping of transcriptomes 15 ), an approach that could readily be combined with ECCITE-seq. The method we describe is inherently customizable and we envisage additional oligo-tagged ligands, such as peptideloaded major histocompatibility complexes for detecting specific TCRs, labeled antigens for detection of antigen specific B cells or antibodies directed against intracellular proteins being added to future iterations of this system. The combination of Cell Hashing together with direct sgRNA capture will enhance perturbation screens with single-cell readouts by allowing the analysis of greater numbers of cells for a given budget. The 'super-loading' afforded by this knowledge will additionally drive down the per-cell cost of single-cell CRISPR screens, which will also require fewer cells per guide to detect expression phenotypes that feature both protein and mRNA. The modular nature of ECCITE-seq allows the tailoring of readouts of such screens, potentially enabling the investigator to interrogate panels of transcripts and proteins of interest in response to their perturbations in addition to, or instead of, the transcriptome. This is in line with the high-dimensional phenotyping of multiple proteins in CRISPR-based pooled screens using Pro-Codes and CyTOF as readout 16 . While this method can more economically achieve precise quantification of intracellular and extracellular protein levels in millions of single cells, it cannot interrogate the single-cell transcriptome simultaneously, it lacks the scalability of DNA barcoding and requires sgRNA cloning in special constructs. ECCITE-seq is readily applicable with minor modifications to any sgRNA library with a 3′ invariant scaffold sequence and, by allowing direct capture of sgRNA molecules, overcomes documented problems of barcode swapping events observed with Perturb-seq 7 . While this work was under review, a conceptually similar method to capture sgRNAs in the context of scRNA-seq was described in ref. 17 . Direct guide capture allows compatibility with applications using multiple different guides per cell; for example, combinatorial screens targeting more than one gene per cell 18, 19 or lineage tracing using multiple homing sgRNAs 20 . Our approach additionally provides a roadmap for targeted capture of specific RNA molecules including non-polyadenylated transcripts.
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Methods
See Protocol Exchange (https://doi.org/10.1038/protex.2019.025) and Supplementary Protocol for a step-by-step protocol for ECCITE-seq.
Antibody-oligo conjugates. Antibodies used for CITE-seq and Cell Hashing were obtained as purified, unconjugated reagents from BioLegend and were covalently and irreversibly conjugated to barcode oligos by iEDDA-click chemistry as previously described 10, 21 . See Supplementary Tables 3-5 for a list of antibodies, clones and barcodes used for ECCITE-seq.
Cell staining with barcoded antibodies. Cells were stained with barcoded antibodies as previously described for CITE-seq 8 and Cell Hashing 10 . Briefly, approximately 1.5-2 million cells per sample were resuspended in 1× CITE-seq staining buffer (2% BSA, 0.01% Tween in PBS) and incubated for 10 min with Fc receptor block (TruStain FcX, BioLegend) to block FC receptor-mediated binding. Subsequently, cells were incubated with mixtures of barcoded antibodies for 30 min at 4 °C. Antibody concentrations were 1 µg per test, as recommended by the manufacturer (BioLegend) for flow cytometry applications. For some highly expressed markers, tags can take up unacceptably high proportions of the proteintag libraries. In these cases (determined empirically from previous experiments), we reduced the concentration of the oligo-tagged antibodies in the panel by diluting with un-tagged antibody. Oligo-labeled CD44 and CD45 were diluted 1:10 and therefore used at an effective concentration of 0.1 µg per stain. After staining, cells were washed three times by resuspension in PBS containing 2% BSA and 0.01% Tween, followed by centrifugation (300g 5 min at 4 °C) and supernatant exchange. After the final wash, cells were resuspended in PBS and filtered through 40 µm cell strainers.
ECCITE-seq on a 10x Genomics instrument. Stained and washed cells were loaded into a 10x Genomics single-cell V(D)J workflow and processed according to the manufacturer's instructions with the following modifications:
(1) 12 pmol of an reverse-transcription primer complementary to sgRNA scaffold sequences was spiked into the reverse-transcription reaction (only when sgRNA capture was desired). gd_RT_v4: AGCAAGTGAGAAGCATCGTGT-CAAAGCACCGACTCGGTGCCAC. (2) During the complementary DNA (cDNA) amplification step, 1 pmol of hashtag additive (GTGACTGGAGTTCAGACGTGTGCTC), 1 pmol of guide-tag additive (AGCAAGTGAGAAGCATCGTGTC) (only when sgRNA capture was desired) and 2 pmol of protein-tag additive primers (CCTTG-GCACCCGAGAATTCC) were spiked into the cDNA amplification PCR. (3) Following PCR, 0.6× solid phase reversible immobilization (SPRI) beads were used to separate the large cDNA fraction derived from cellular mRNAs (retained on beads) from the protein-tag-, hashtag-and guide-tag-containing fraction (in supernatant). The complementary DNA fraction was processed according to the 10x Genomics Single-Cell V(D)J protocol to generate the transcriptome library and the TCR α/β library. To amplify TCR γ/δ transcripts we implemented a strategy similar to TCR α/β approach from 10x Genomics with a two-step PCR: during target enrichment 1 we used SI-PCR (AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACAC-GACGCTC) and a mix of R1_hTRDC (AGCTTGACAGCATTGTACTTCC) and R1_hTRGC (TGTGTCGTTAGTCTTCATGGTGTTCC), followed by target enrichment 2 with a generic P5 oligo (AATGATACGGCGACCAC-CGAGATCTACAC) and a mix of R2_hTRDC (TCCTTCACCAGACAAGC-GAC) and R2_hTRGC (GATCCCAGAATCGTGTTGCTC). cDNA and TCR (α/β and γ/δ) enriched libraries were further processed according to the 10x Genomics Single-Cell V(D)J protocol. (4) An additional 1.4× reaction volume of SPRI beads was added to the protein-tag/hashtag/guide-tag fraction from step 3, to bring the ratio up to 2.0×. Beads were washed with 80% ethanol, eluted in water and an additional round of 2.0× SPRI performed to remove excess single-stranded oligonucleotides carried over from the cDNA amplification reaction. After final elution, separate PCR reactions were set up to generate the proteintag library (SI-PCR and RPI-x primers), the hashtag library (SI-PCR and D7xx_s) and the guide-tag library (SI-PCR and Next_nst_x). The protein-tag and hashtag libraries were prepared as previously described 10 . Following the cDNA amplification, the sgRNA sequences are converted to an Illumina library by amplification with smRNA_nst_x (v. cycles index, 91 cycles read 2). Reads were trimmed as required for downstream processing. A detailed and regularly updated point-by-point protocol for CITE-seq, Cell Hashing, ECCITE-seq and future updates can be found at www.cite-seq.com and on the Nature Protocol Exchange.
Cells.
The samples from the patient and the control were collected at New York University Langone Medical Center in accordance with protocols approved by the New York University School of Medicine Institutional Review Board and Bellevue Facility Research Review Committee (IRB no. i15-01162). Patients with CTCL were diagnosed according to the WHO classification criteria. After written informed consent was obtained, peripheral blood samples were harvested. PBMCs were isolated from the blood of patients and healthy controls by gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) and Sepmate-50 tubes (Stemcell). Buffy coat PBMCs were collected and washed twice with PBS 2% FBS and cryopreserved in freezing medium (40% Roswell Park Memorial Institute medium (RPMI) 1640, 50% FBS and 10% DMSO). Cryopreserved PBMCs were thawed for 1-2 min in a 37 °C water bath, washed twice in warm PBS 2% FBS and resuspended in complete medium (RPMI 1640 supplemented with 10% FBS and 2 mM L-Glut). Control and CTCL PBMCs were stained with a 49-antibody panel (Supplementary Table 3 ) and Cell Hashing antibodies (Supplementary Table 5 ), before loading into two separate 10x Genomics Chromium lanes.
The Sez4 cell line is derived from the blood of a patient with Sézary syndrome 22 , and the MyLa 2059 line is derived from a plaque biopsy sample of a patient with mycosis fungoides 23 . Sez4 cells were cultured in RPMI 1640 medium with 2 mM l-glutamine, 1% Pen/Strep, 500 units per ml of rh IL-2 (Corning) and 10% human serum. MyLa 2059 cells were cultured in RPMI 1640 medium with 2 mM l-glutamine, 1% Pen/Strep and 10% fetal bovine serum. All cells were incubated at 37 °C, 5% CO 2 in a humidified incubator. The cells were cryopreserved in 90% FBS 10% DMSO and aliquots of 1-1.5 million cells were thawed on the day of the experiment. PBMCs were obtained cryopreserved from AllCells and used immediately after thawing. NIH-3T3 and HEK293FT cells expressing non-targeting sgRNAs were maintained according to standard procedures in Dulbecco's Modified Eagle's Medium (Thermo Fisher) supplemented with 10% fetal bovine serum (Thermo Fisher) and 1 µg ml −1 puromycin, at 37 °C with 5% CO 2 . K562 cells expressing targeting and non-targeting guides were maintained in RPMI supplemented with 10% fetal bovine serum and 1 µg ml −1 puromycin, at 37 °C with 5% CO 2 .
Lentivirus production and transduction. DNA oligos encoding the sgRNAs were individually synthesized (Integrated DNA Technologies) and cloned into the lentiviral transfer vector LentiCRISPR v.2 (ref. 24 ) (Addgene Plasmid: 52961). Equal amounts of each sgRNA vector were mixed and packaged into lentiviral particles through transfection with packaging plasmids in HEK293FT cells, as previously described 25 . For transduction of HEK293FT, the lentiviral guide pool consisted of ten non-targeting human guides in one experiment and 10 non-targeting and 11 gene-targeting human guides in another experiment (Supplementary Table 1 ). For transduction of K562, the pool consisted of 2 non-targeting and 11 targeting human guides (Supplementary Table 1 ). For transduction of NIH-3T3, the pool consisted of 10 non-targeting mouse guides (Supplementary Table 2) . NIH-3T3, HEK293FT and K562 cells were infected at multiplicity of infection = 0.05 and selected and maintained in 1 µg ml −1 puromycin. NIH-3T3 cells used in the proof-of-principle experiment were maintained in culture for several weeks, allowing drift in the representation of guides. Following transduction, K562 cells were stored in liquid nitrogen and were allowed to grow for 2 days before the ECCITE-seq run.
Single-cell data processing. Fastq files from the 10x libraries with four distinct barcodes were pooled together and processed using the cellranger count pipeline, v.2.1.1. Reads were aligned to the GRCh38 (human healthy and CTCL PBMC datasets) or hg19-mm10 concatenated reference (human-mouse experiment). For protein-tag, hashtag and guide-tag quantification, we used a previously developed tag quantification pipeline (v.1.3.2), available at https://github.com/Hoohm/CITEseq-Count, run with default parameters (maximum Hamming distance of 1). For the TCR libraries, fastq files from the 10x libraries with four distinct barcodes were pooled together, processed using the cellranger vdj pipeline and reads were aligned to the GRCh38 reference genome.
Seurat. Normalization and downstream analysis of RNA data were performed using the Seurat R package (v.2.3.0) 13 , which enables the integrated processing of multimodal single-cell datasets. Protein-tag, hashtag and guide-tag raw counts were normalized using centered log ratio transformation, where counts were divided by the geometric mean of the corresponding tag across cells and logtransformed 8 . For demultiplexing based on hashtag or guide-tag counts we used the HTODemux function within the Seurat package as described 10 . To calculate the significance in detecting the target gene-expression change between the targeting guide clusters and the non-targeting clusters we used FindAllMarkers with maximum cell number ranging from 10-100, in ten sampling iterations for each cell number. For the TCR libraries, productive clonotypes were filtered and their raw counts were inserted into the Seurat object under a new assay slot. Raw counts were normalized using centered log ratio transformation and scaled. For comparison between the healthy donor and CTCL data, both Seurat objects were merged and depth-normalized when performing cell alignment (or batch normalization) using RunCCA with a default parameter of 30 canonical vectors 13 . The top ten aligned components were used for visualization with t-SNE (t-distributed stochastic neighbor embedding) as well as clustering with modularity optimization. The top 20 genes upregulated in each cluster (FindAllMarkers) was used to label the cluster. For protein-tag clustering, distance matrices of the combined object were computed before generating t-SNE plots.
Definition of CD4 T cells and Malignant clone.
In an analogous strategy to what is used for data visualization in flow cytometry, biaxial KDE plots were made using log(protein-tag counts + 1) of CD3 and CD4. Cells in both samples were gated at a threshold ≥4.5 (log scale) for CD4 protein-tag counts and ≥1.0 (log scale) for CD3 protein-tag counts, defining CD4 + T cells. CTCL Malignant cells were defined as CD4 T cells that possessed the most abundant TCRβ CDR3 amino acid sequence, CSARFLRGGYNEQFF, while CTCL CD4 polyclonal cells were CD4 T cells that did not possess this sequence.
Single-cell differential analysis. Comparisons were done using Wilcoxon rank sum test (FindMarkers) between 'CTCL Malignant' and 'CTCL CD4 polyclonal' as well as between 'CTCL Malignant' and 'control CD4 Normal' . Significant genes were defined using q value <0.05 and |avg_log 2 The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Data analysis
To make the protein and guide oligo tag tables we used CITE-seq count, version 1.3.2: https://github.com/Hoohm/CITE-seq-Count. Gene expression tables were prepared using the cellranger count pipeline, and TCR libraries were processed using the cellranger vdj pipeline. For multimodal analysis we used the Seurat package, version 2.3.0.
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